Rescue of Long-Term Spatial Memory by 7,8-Dihydroxyflavone in Mice with Reduced Oligodendrogenesis
eNeuro. 2023 May 5;10(5):ENEURO.0498-22.2023. doi: 10.1523/ENEURO.0498-22.2023. Print 2023 May. ABSTRACT Oligodendrogenesis is the process by which new oligodendrocytes are produced in the CNS. Oligodendrocytes form myelin, which has a vital role in neural signal transmission and integration. Here we tested mice with reduced adult oligodendrogenesis in the Morris water maze, a test of spatial learning. […]
Chronic Stress Alters Hippocampal Renin-Angiotensin-Aldosterone System Component Expression in an Aged Rat Model of Wolfram Syndrome
Genes (Basel). 2023 Mar 30;14(4):827. doi: 10.3390/genes14040827. ABSTRACT Biallelic mutations in the gene encoding WFS1 underlie the development of Wolfram syndrome (WS), a rare neurodegenerative disorder with no available cure. We have previously shown that Wfs1 deficiency can impair the functioning of the renin-angiotensin-aldosterone system (RAAS). The expression of two key receptors, angiotensin II receptor […]
Wfs1 loss-of-function disrupts the composition of mouse pancreatic endocrine cells from birth and impairs Glut2 localization to cytomembrane in pancreatic β cells
Biochem Biophys Res Commun. 2023 May 28;658:80-87. doi: 10.1016/j.bbrc.2023.03.074. Epub 2023 Mar 31. ABSTRACT Wfs1 is an endoplasmic reticulum (ER) membrane located protein highly expressed in pancreatic β cells and brain. Wfs1 deficiency causes adult pancreatic β cells dysfunction following β cells apoptosis. Previous studies mainly focus on the Wfs1 function in adult mouse pancreatic […]
GLP1 receptor agonists for Wolfram syndrome?
Nat Rev Endocrinol. 2023 Apr 19. doi: 10.1038/s41574-023-00839-y. Online ahead of print. NO ABSTRACT PMID:37076572 | DOI:10.1038/s41574-023-00839-y
WFS1 autosomal dominant variants linked with hearing loss: update on structural analysis and cochlear implant outcome
BMC Med Genomics. 2023 Apr 11;16(1):79. doi: 10.1186/s12920-023-01506-x. ABSTRACT BACKGROUND: Wolfram syndrome type 1 gene (WFS1), which encodes a transmembrane structural protein (wolframin), is essential for several biological processes, including proper inner ear function. Unlike the recessively inherited Wolfram syndrome, WFS1 heterozygous variants cause DFNA6/14/38 and wolfram-like syndrome, characterized by autosomal dominant nonsyndromic hearing loss, […]
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Diabetologia. 2023 Mar 30. doi: 10.1007/s00125-023-05905-8. Online ahead of print. ABSTRACT AIMS/HYPOTHESIS: Wolfram syndrome is a rare autosomal recessive disorder caused by pathogenic variants in the WFS1 gene. It is characterised by insulin-dependent diabetes mellitus, optic nerve atrophy, diabetes insipidus, hearing loss and neurodegeneration. Considering the unmet treatment need for this orphan disease, this study […]
Evaluation of the Oral Bacterial Genome and Metabolites in Patients with Wolfram Syndrome
Int J Mol Sci. 2023 Mar 15;24(6):5596. doi: 10.3390/ijms24065596. ABSTRACT In Wolfram syndrome (WFS), due to the loss of wolframin function, there is increased ER stress and, as a result, progressive neurodegenerative disorders, accompanied by insulin-dependent diabetes. The aim of the study was to evaluate the oral microbiome and metabolome in WFS patients compared with […]
Generation of induced pluripotent stem cells (IBMSi027-A) from a patient with hearing loss carrying WFS1 c.2051C > T (p.Ala684Val) variant
Stem Cell Res. 2023 Mar 16;69:103068. doi: 10.1016/j.scr.2023.103068. Online ahead of print. ABSTRACT Pathogenic variants of the WFS1 gene can cause recessive-inherited Wolfram syndrome or dominant-inherited Wolfram-like syndrome with optic atrophy and hearing impairment. Using the Sendai virus delivery system, we generated induced pluripotent stem cells from the peripheral blood mononuclear cells of a female […]
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
Autoimmun Rev. 2023 Mar 14:103312. doi: 10.1016/j.autrev.2023.103312. Online ahead of print. ABSTRACT More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, […]
WFS1 Spectrum Disorder
2009 Feb 24 [updated 2022 Dec 1]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. ABSTRACT CLINICAL CHARACTERISTICS: WFS1 spectrum disorder (WFS1-SD) comprises classic WFS1 spectrum disorder and nonclassic WFS1 spectrum disorder. Classic WFS1-SD, a progressive […]